311 related articles for article (PubMed ID: 30959953)
1. Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.
Santana Machado T; Cerini C; Burtey S
Toxins (Basel); 2019 Apr; 11(4):. PubMed ID: 30959953
[TBL] [Abstract][Full Text] [Related]
2. Aryl Hydrocarbon Receptor Activation in Chronic Kidney Disease: Role of Uremic Toxins.
Brito JS; Borges NA; Esgalhado M; Magliano DC; Soulage CO; Mafra D
Nephron; 2017; 137(1):1-7. PubMed ID: 28490014
[TBL] [Abstract][Full Text] [Related]
3. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease.
Sallée M; Dou L; Cerini C; Poitevin S; Brunet P; Burtey S
Toxins (Basel); 2014 Mar; 6(3):934-49. PubMed ID: 24599232
[TBL] [Abstract][Full Text] [Related]
4. Aryl Hydrocarbon Receptor and Uremic Toxins from the Gut Microbiota in Chronic Kidney Disease Patients: Is There a Relationship between Them?
Brito JS; Borges NA; Anjos JSD; Nakao LS; Stockler-Pinto MB; Paiva BR; Cardoso-Weide LC; Cardozo LFMF; Mafra D
Biochemistry; 2019 Apr; 58(15):2054-2060. PubMed ID: 30912928
[TBL] [Abstract][Full Text] [Related]
5. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.
Gondouin B; Cerini C; Dou L; Sallée M; Duval-Sabatier A; Pletinck A; Calaf R; Lacroix R; Jourde-Chiche N; Poitevin S; Arnaud L; Vanholder R; Brunet P; Dignat-George F; Burtey S
Kidney Int; 2013 Oct; 84(4):733-44. PubMed ID: 23636172
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells.
Addi T; Poitevin S; McKay N; El Mecherfi KE; Kheroua O; Jourde-Chiche N; de Macedo A; Gondouin B; Cerini C; Brunet P; Dignat-George F; Burtey S; Dou L
Arch Toxicol; 2019 Jan; 93(1):121-136. PubMed ID: 30324315
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases.
Liu B; Luo F; Luo X; Duan S; Gong Z; Peng J
Curr Drug Metab; 2018; 19(7):568-576. PubMed ID: 29299983
[TBL] [Abstract][Full Text] [Related]
8. Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.
Santana Machado T; Poitevin S; Paul P; McKay N; Jourde-Chiche N; Legris T; Mouly-Bandini A; Dignat-George F; Brunet P; Masereeuw R; Burtey S; Cerini C
J Am Soc Nephrol; 2018 Mar; 29(3):906-918. PubMed ID: 29222397
[TBL] [Abstract][Full Text] [Related]
9. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.
Dou L; Poitevin S; Sallée M; Addi T; Gondouin B; McKay N; Denison MS; Jourde-Chiche N; Duval-Sabatier A; Cerini C; Brunet P; Dignat-George F; Burtey S
Kidney Int; 2018 Apr; 93(4):986-999. PubMed ID: 29395338
[TBL] [Abstract][Full Text] [Related]
10. 1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway.
Miao H; Wu XQ; Wang YN; Chen DQ; Chen L; Vaziri ND; Zhuang S; Guo Y; Su W; Ma SX; Zhang HQ; Shang YQ; Yu XY; Zhao YL; Mao JR; Gao M; Zhang JH; Zhao J; Zhang Y; Zhang L; Zhao YY; Cao G
Br J Pharmacol; 2022 Jan; 179(1):103-124. PubMed ID: 34625952
[TBL] [Abstract][Full Text] [Related]
11. Effect of Dialysis on Aryl Hydrocarbon Receptor Transactivating Activity in Patients with Chronic Kidney Disease.
Kim JT; Kim SH; Min HK; Jeon SJ; Sung SA; Park WH; Lee HK; Choi HS; Pak YK; Lee SY
Yonsei Med J; 2020 Jan; 61(1):56-63. PubMed ID: 31887800
[TBL] [Abstract][Full Text] [Related]
12. Uremic toxins mediate kidney diseases: the role of aryl hydrocarbon receptor.
Xie H; Yang N; Yu C; Lu L
Cell Mol Biol Lett; 2024 Mar; 29(1):38. PubMed ID: 38491448
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats.
Lu H; Lei X; Klaassen C
Kidney Int; 2006 Dec; 70(11):1920-8. PubMed ID: 16985511
[TBL] [Abstract][Full Text] [Related]
14. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
Ladda MA; Goralski KB
Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
[TBL] [Abstract][Full Text] [Related]
15. Role of the aryl hydrocarbon receptor in drug metabolism.
Ramadoss P; Marcus C; Perdew GH
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):9-21. PubMed ID: 16922649
[TBL] [Abstract][Full Text] [Related]
16. Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.
Chapron A; Shen DD; Kestenbaum BR; Robinson-Cohen C; Himmelfarb J; Yeung CK
Clin Transl Sci; 2017 Sep; 10(5):395-403. PubMed ID: 28675584
[TBL] [Abstract][Full Text] [Related]
17. Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factor‒dependent erythropoietin expression through activation of aryl hydrocarbon receptor.
Asai H; Hirata J; Watanabe-Akanuma M
Biochem Biophys Res Commun; 2018 Oct; 504(2):538-544. PubMed ID: 30205954
[TBL] [Abstract][Full Text] [Related]
18. [Drug pharmacokinetics in renal failure: What's new?].
Naud J; Dumayne C; Nolin TD; Leblond FA; Pichette V
Nephrol Ther; 2015 Jun; 11(3):144-51. PubMed ID: 25861715
[TBL] [Abstract][Full Text] [Related]
19. The kidney and uremic toxin removal: glomerulus or tubule?
Masereeuw R; Mutsaers HA; Toyohara T; Abe T; Jhawar S; Sweet DH; Lowenstein J
Semin Nephrol; 2014 Mar; 34(2):191-208. PubMed ID: 24780473
[TBL] [Abstract][Full Text] [Related]
20. The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?
Mo Y; Lu Z; Wang L; Ji C; Zou C; Liu X
Front Cell Dev Biol; 2020; 8():589752. PubMed ID: 33415104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
